^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MET positive

    i
    Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
    Entrez ID:
    4233
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (NCT04310007)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    07/13/2020
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    EGFR • PD-L1 • KRAS • BRAF • ALK • ROS1
    |
    KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative
    |
    Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • lexatumumab (ETR2-ST01) • liposomal gemcitabine (FF-10832)
    A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 (BYON3521.001) (NCT05323045)
    Phase 1
    Byondis B.V.
    Active, not recruiting
    Last update posted :
    06/07/2024
    Initiation :
    03/21/2022
    Primary completion :
    07/01/2024
    Completion :
    07/01/2024
    MET
    |
    MET amplification • MET mutation • MET expression • MET positive
    |
    BYON3521
    A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors (NCT04617314)
    Phase 1
    RemeGen Co., Ltd.
    Recruiting
    Last update posted :
    02/20/2024
    Initiation :
    03/10/2021
    Primary completion :
    05/31/2025
    Completion :
    12/31/2025
    MET
    |
    MET positive
    |
    RC108
    A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor (NCT05628857)
    Phase 2
    RemeGen Co., Ltd.
    Recruiting
    Last update posted :
    11/30/2023
    Initiation :
    11/11/2022
    Primary completion :
    10/15/2024
    Completion :
    10/15/2025
    MET
    |
    MET positive
    |
    RC108
    A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy (HS-10241-301) (NCT06110663)
    Phase 3
    Jiangsu Hansoh Pharmaceutical Co., Ltd.
    Not yet recruiting
    Last update posted :
    11/01/2023
    Initiation :
    12/30/2023
    Primary completion :
    12/30/2024
    Completion :
    02/28/2025
    MET
    |
    EGFR mutation • EGFR L858R • EGFR T790M • MET positive
    |
    cisplatin • carboplatin • pemetrexed • Ameile (aumolertinib) • dalmelitinib (HS-10241)
    Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC (NCT05430386)
    Phase 1
    Jiangsu Hansoh Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    02/14/2023
    Initiation :
    01/05/2022
    Primary completion :
    12/31/2023
    Completion :
    12/31/2023
    MET
    |
    EGFR L858R • EGFR exon 19 deletion • MET mutation • MET positive • EGFR T790M negative • EGFR mutation + MET-CEP7 fusion • MET positive + EGFR mutation
    |
    Ameile (aumolertinib) • dalmelitinib (HS-10241)
    Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors (NCT04930432)
    Phase 1/2
    Betta Pharmaceuticals Co., Ltd.
    Recruiting
    Last update posted :
    12/21/2021
    Initiation :
    09/24/2021
    Primary completion :
    06/30/2024
    Completion :
    06/30/2025
    EGFR • IFNG • IL6 • TNFA • CXCL8 • IL2 • IL10 • IL1B
    |
    MET positive
    |
    pamvatamig (MCLA-129)
    Lung-MAP S1400K: c-MET Positive (LUNG-MAP SUB-STUDY) (NCT03574753)
    Phase 2
    Southwest Oncology Group
    Completed
    Last update posted :
    10/18/2021
    Initiation :
    03/16/2018
    Primary completion :
    12/21/2019
    Completion :
    07/30/2021
    MET
    |
    MET positive
    |
    Emrelis (telisotuzumab vedotin-tllv)
    A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors (NCT01999972)
    Phase 1b
    Pfizer
    Completed
    Last update posted :
    09/24/2020
    Initiation :
    02/26/2014
    Primary completion :
    02/22/2017
    Completion :
    09/05/2019
    MET • HGF • FLT4
    |
    MET positive
    |
    Xalkori (crizotinib) • axitinib
    Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161 (NCT04228406)
    Phase 1
    Fujian Cosunter Pharmaceutical Co. Ltd
    Unknown status
    Last update posted :
    01/14/2020
    Initiation :
    07/01/2019
    Primary completion :
    09/30/2020
    Completion :
    12/31/2020
    MET
    |
    MET amplification • MET expression • MET positive
    |
    gemnelatinib (GST-HG161)